Publika - Scientific publications from Oslo University Hospital

RSS feed RSS

Publications (original articles or review articles) published in 2021 from OUS - Genetics (Lothe)

12 publications found

Berg KCG, Brunsell TH, Sveen A, Alagaratnam S, Bjørnslett M, Hektoen M, Brudvik KW, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA (2021)
Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases
Mol Oncol, 15 (4), 830-845
DOI 10.1002/1878-0261.12885, PubMed 33325154

Bruun J, Eide PW, Bergsland CH, Bruck O, Svindland A, Arjama M, Välimäki K, Bjørnslett M, Guren MG, Kallioniemi O, Nesbakken A, Lothe RA, Pellinen T (2021)
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
Mol Oncol
DOI 10.1002/1878-0261.13159, PubMed 34890102

Eide PW, Moosavi SH, Eilertsen IA, Brunsell TH, Langerud J, Berg KCG, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA, Sveen A (2021)
Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
NPJ Genom Med, 6 (1), 59
DOI 10.1038/s41525-021-00223-7, PubMed 34262039

Gansmo LB, Sofiyeva N, Bjørnslett M, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
Sci Rep, 11 (1), 23463
DOI 10.1038/s41598-021-02820-z, PubMed 34873230

Helwa R, Gansmo LB, Bjørnslett M, Halle MK, Werner HMJ, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
Biomarkers, 26 (4), 302-308
DOI 10.1080/1354750X.2021.1891291, PubMed 33645339

Kidd SG, Carm KT, Bogaard M, Olsen LG, Bakken AC, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI (2021)
High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity
Neoplasia, 23 (6), 634-641
DOI 10.1016/j.neo.2021.05.012, PubMed 34107378

Kryeziu K, Moosavi SH, Bergsland CH, Guren MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen A, Lothe RA (2021)
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
J Transl Med, 19 (1), 384
DOI 10.1186/s12967-021-03062-3, PubMed 34496878

Moosavi SH, Eide PW, Eilertsen IA, Brunsell TH, Berg KCG, Røsok BI, Brudvik KW, Bjørnbeth BA, Guren MG, Nesbakken A, Lothe RA, Sveen A (2021)
De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
Genome Med, 13 (1), 143
DOI 10.1186/s13073-021-00956-1, PubMed 34470666

Pluta J, Pyle LC, Nead KT, Wilf R, Li M, Mitra N, Weathers B, D'Andrea K, Almstrup K, Anson-Cartwright L, Benitez J, Brown CD, Chanock S, Chen C, Cortessis VK, Ferlin A, Foresta C, Gamulin M, Gietema JA, Grasso C, Greene MH, Grotmol T, Hamilton RJ, Haugen TB, Hauser R et al. (2021)
Identification of 22 susceptibility loci associated with testicular germ cell tumors
Nat Commun, 12 (1), 4487
DOI 10.1038/s41467-021-24334-y, PubMed 34301922

Slørdahl KS, Klotz D, Olsen JÅ, Skovlund E, Undseth C, Abildgaard HL, Brændengen M, Nesbakken A, Larsen SG, Hanekamp BA, Holmboe L, Tvedt R, Sveen A, Lothe RA, Malinen E, Kaasa S, Guren MG (2021)
Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
Acta Oncol, 60 (7), 921-930
DOI 10.1080/0284186X.2021.1918763, PubMed 33966592

Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021)
The expressed mutational landscape of microsatellite stable colorectal cancers
Genome Med, 13 (1), 142
DOI 10.1186/s13073-021-00955-2, PubMed 34470667

Aasebø K, Bruun J, Bergsland CH, Nunes L, Eide GE, Pfeiffer P, Dahl O, Glimelius B, Lothe RA, Sorbye H (2021)
Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients
Br J Cancer, 126 (1), 48-56
DOI 10.1038/s41416-021-01586-5, PubMed 34671130

0.12s